How can patients be empowered to manage their condition while on eculizumab?

Feb 22, 2023 ... This study demonstrates that the majority of patients benefit from eculizumab when adhering to the indications as formulated in the Dutch PNH guideline. Aug 15, 2018 ... Reported relapse rates in aHUS after stopping eculizumab are as high as 30%, suggesting indefinite therapy is reasonable and that patients who choose to stop ... Apr 6, 2025 ... Eculizumab, a humanized anti-C5 monoclonal antibody, has been the standard of care for treating aHUS, and has been shown to be effective in ... Aug 24, 2023 ... Pioneering treatment highly effective for rare kidney disease ... A pioneering drug for a rare kidney disease prevents organ failure and ... The SOLIRIS Infusion Finder provides access to a locator tool, which shows sites providing infusion services. Why is Soliris authorised in the EU? Soliris was shown to benefit patients with these rare diseases. The safety profile was similar for all the diseases and was ... Your browsing activity is empty. Activity recording is turned off. Turn recording back on. See more... Follow NCBI. Connect with NLM. National Library of ... Apr 7, 2025 ... ... Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris ® in the U.S. Teva and Samsung Bioepis entered into ... Dec 12, 2022 ... It may be given to your child for other reasons. Talk with the doctor. Eculizumab. 2/11. Page 3 ... The generic drug name is eculizumab (ek-u-liz-oo-mab). Soliris® is a brand ... Eculizumab is a monoclonal antibody, a type of targeted therapy. It.